| 产品编号 |
英文名称 |
CAS号 |
产品规格 |
价格 |
货期 |
| ZMR-15-1511 |
(3aR,8aR)-(-)-4,4,8,8-Tetrakis(3,5-dimethylphenyl)tetrahydro-2,2-dimethyl-6-phenyl-1,3-dioxolo[4,5-e]dioxaphosphepin |
[1019840-96-0] |
100mg |
咨询 |
3-5周 |
| ZMR-15-1505 |
(3aR,8aR)-(-)-(2,2-Dimethyl-4,4,8,8-tetraphenyl-tetrahydro-[1,3]dioxolo[4,5-e][1,3,2]dioxaphosphepin-6-yl)dimethylamine, min. 98% |
[213843-90-4] |
100mg |
咨询 |
3-5周 |
| ZMR-15-1513 |
(3aR,8aR)-(-)-4,4,8,8-Tetrakis(3,5-di-i-propylphenyl)tetrahydro-2,2-dimethyl-6-phenyl-1,3-dioxolo[4,5-e]dioxaphosphepin |
[1361146-90-8] |
100mg |
咨询 |
3-5周 |
| ZMR-15-1517 |
(3aR,8aR)-(-)-4,4,8,8-Tetrakis(3,5-diethylphenyl)tetrahydro-2,2-dimethyl-6-phenyl-1,3-dioxolo[4,5-e]dioxaphosphepin |
[1187446-93-0] |
100mg |
咨询 |
3-5周 |
| ZMR-15-8625 |
(3aR,8aR)-4,4,8,8-Tetrakis(3,5-di-tert-butylphenyl)-2,2-bis(4-fluorophenyl)-6-hydroxy-tetrahydro-6-oxide-[1,3]dioxolo[4,5-e][1,3,2]dioxaphosphepine, 98%, (99% ee) |
N/A |
100mg |
咨询 |
3-5周 |
| ZMR-15-8629 |
(3aR,8aR)-4,4,8,8-Tetrakis(3,5-di-tert-butylphenyl)-2,2-bis(4-chlorophenyl)-6-hydroxy-tetrahydro-6-oxide-[1,3]dioxolo[4,5-e][1,3,2]dioxaphosphepine, 95%, (99% ee) 95%, (99% ee) |
N/A |
100mg |
咨询 |
3-5周 |
| ZMR-15-8638 |
(3aR,8aR)-4,4,8,8-Tetrakis(3,5-di-tert-butylphenyl)-6-hydroxy-2,2-di-p-tolyltetrahydro-6-oxide-[1,3]dioxolo[4,5-e][1,3,2]dioxaphosphepine, 98%, (99% ee) |
N/A |
100mg |
咨询 |
3-5周 |
| ZMR-15-8634 |
(3aR,8aR)-4,4,8,8-Tetrakis(3,5-di-tert-butylphenyl)-6-hydroxy-2,2-bis(4-(trifluoromethyl)phenyl)tetrahydro-6-oxide-[1,3]dioxolo[4,5-e][1,3,2]dioxaphosphepine, 98% |
N/A |
100mg |
咨询 |
3-5周 |
| ZMR-15-8617 |
(3aR,8aR)-Tetrahydro-6-hydroxy-2,2-dimethyl-4,4,8,8-tetrakis(3,5-di-tert-butylphenyl)-6-oxide-[1,3]dioxolo[4,5-e][1,3,2]dioxaphosphepine, 98%, (99% ee) |
N/A |
100mg |
咨询 |
3-5周 |
| ZMR-15-8612 |
(3aR,8aR)-Tetrahydro-6-hydroxy-2,2-dimethyl-4,4,8,8-tetrakis(3,5-diisopropyl-4-methoxyphenyl)-6-oxide-[1,3]dioxolo[4,5-e][1,3,2]dioxaphosphepine, 98% |
N/A |
100mg |
咨询 |
3-5周 |
| ZMR-15-8608 |
(3aR,8aR)-Tetrahydro-6-hydroxy-2,2-dimethyl-4,4,8,8-tetrakis(4-(tert-butyl)phenyl)-6-oxide-[1,3]dioxolo[4,5-e][1,3,2]dioxaphosphepine, 98%, (99% ee) |
N/A |
100mg |
咨询 |
3-5周 |
| ZMR-15-8602 |
(3aR,8aR)-Tetrahydro-6-hydroxy-2,2-dimethyl-4,4,8,8-tetra-2-naphthalenyl-6-oxide-1,3-dioxolo[4,5-e][1,3,2]dioxaphosphepin, 98%, (99% ee) |
[952649-50-2] |
100mg |
咨询 |
3-5周 |
| ZMR-07-1034 |
(3aS,3'aS,8aR,8'aR)-2,2'-(1-Methylethylidene)bis[3a,8a-dihydro-8H-indeno[1,2-d]oxazole], 98%, (99% ee) |
[175166-51-5] |
100mg |
咨询 |
3-5周 |
| ZMR-07-1395 |
(3aS,3'aS,8aR,8'aR)-2,2'-Cyclohexylidenebis[3a,8a-dihydro-8H-indeno[1,2-d]oxazole, 98%, (99% ee) |
N/A |
50mg |
咨询 |
3-5周 |
| ZMR-07-1404 |
(3aS,3a'S,8aR,8a'R)-2,2'-(1,3-Dihydro-2H-inden-2-ylidene)bis[3a,8a-dihydro-8H-indeno[1,2-d]oxazole], 98%, (99% ee) |
[188780-28-1] |
50mg |
咨询 |
3-5周 |
| ZMR-07-1228 |
(3aS,3a'S,8aR,8a'R)-2,2'-(1,3-Bis(3,5-di-t-butylphenyl)propane-2,2-diyl)bis(8,8a-dihydro-3aH-indeno[1,2-d]oxazole) (S,R)-BDTBIn-SaBOX |
[1435467-29-0] |
100mg |
咨询 |
3-5周 |
| ZMR-07-1409 |
(3aS,3'aS,8aR,8'a'R)-2,2'-Cyclopropylidenebis[3a,8a-dihydro-8H-Indeno[1,2-d]oxazole], 98%, (99% ee) |
[182122-08-3] |
50mg |
咨询 |
3-5周 |
| ZMR-07-1381 |
(3aS,3'aS,8aR,8'aR)-2,2'-Cyclopentylidenebis[3a,8a-dihydro-8H-indeno[1,2-d]oxazole], 98%, (99% ee) |
[182122-12-9] |
50mg |
咨询 |
3-5周 |
| ZMR-07-1387 |
(3aS,3a'S,8aR,8a'R)-2,2'-Cyclohexylidenebis[8,8a-dihydro-3aH-indeno[1,2-d]oxazole], 98%, (99% ee) |
[182122-13-0] |
50mg |
咨询 |
3-5周 |
| ZMR-07-1388 |
(3aS,3a'S,8aR,8a'R)-2,2'-Cyclohexylidenebis[8,8a-dihydro-3aH-indeno[1,2-d]oxazole], 98%, (99% ee) |
[182122-13-0] |
50mg |
咨询 |
3-5周 |
| ZMR-15-1514 |
(3aS,8aS)-(+)-4,4,8,8-Tetrakis(3,5-di-i-propylphenyl)tetrahydro-2,2-dimethyl-6-phenyl-1,3-dioxolo[4,5-e]dioxaphosphepin |
[1422371-27-4] |
100mg |
咨询 |
3-5周 |
| ZMR-15-1518 |
(3aS,8aS)-(+)-4,4,8,8-Tetrakis(3,5-diethylphenyl)tetrahydro-2,2-dimethyl-6-phenyl-1,3-dioxolo[4,5-e]dioxaphosphepin |
N/A |
100mg |
咨询 |
3-5周 |
| ZMR-15-1512 |
(3aS,8aS)-(+)-4,4,8,8-Tetrakis(3,5-dimethylphenyl)tetrahydro-2,2-dimethyl-6-phenyl-1,3-dioxolo[4,5-e]dioxaphosphepin |
[1169835-86-2] |
100mg |
咨询 |
3-5周 |
| ZMR-15-8626 |
(3aS,8aS)-4,4,8,8-Tetrakis(3,5-di-tert-butylphenyl)-2,2-bis(4-fluorophenyl)-6-hydroxy-tetrahydro-6-oxide-[1,3]dioxolo[4,5-e][1,3,2]dioxaphosphepine, 98% |
N/A |
100mg |
咨询 |
3-5周 |
| ZMR-15-8630 |
(3aS,8aS)-4,4,8,8-Tetrakis(3,5-di-tert-butylphenyl)-2,2-bis(4-chlorophenyl)-6-hydroxy-tetrahydro-6-oxide-[1,3]dioxolo[4,5-e][1,3,2]dioxaphosphepine, 95%, (99% ee) |
N/A |
100mg |
咨询 |
3-5周 |
| ZMR-15-8639 |
(3aS,8aS)-4,4,8,8-Tetrakis(3,5-di-tert-butylphenyl)-6-hydroxy-2,2-di-p-tolyltetrahydro-6-oxide-[1,3]dioxolo[4,5-e][1,3,2]dioxaphosphepine, 98%, (99% ee) |
N/A |
100mg |
咨询 |
3-5周 |
| ZMR-15-8635 |
(3aS,8aS)-4,4,8,8-Tetrakis(3,5-di-tert-butylphenyl)-6-hydroxy-2,2-bis(4-(trifluoromethyl)phenyl)tetrahydro-6-oxide-[1,3]dioxolo[4,5-e][1,3,2]dioxaphosphepine, 98% |
N/A |
100mg |
咨询 |
3-5周 |
| ZMR-15-8618 |
(3aS,8aS)-Tetrahydro-6-hydroxy-2,2-dimethyl-4,4,8,8-tetrakis(3,5-di-tert-butylphenyl)-6-oxide-[1,3]dioxolo[4,5-e][1,3,2]dioxaphosphepine, 98%, (99% ee) |
N/A |
100mg |
咨询 |
3-5周 |
| ZMR-15-8613 |
(3aS,8aS)-Tetrahydro-6-hydroxy-2,2-dimethyl-4,4,8,8-tetrakis(3,5-diisopropyl-4-methoxyphenyl)-6-oxide-[1,3]dioxolo[4,5-e][1,3,2]dioxaphosphepine, 98% |
N/A |
100mg |
咨询 |
3-5周 |
| ZMR-15-8609 |
(3aS,8aS)-Tetrahydro-6-hydroxy-2,2-dimethyl-4,4,8,8-tetrakis(4-(tert-butyl)phenyl)-6-oxide-[1,3]dioxolo[4,5-e][1,3,2]dioxaphosphepine, 98%, (99% ee) |
N/A |
100mg |
咨询 |
3-5周 |
| ZMR-15-8603 |
(3aS,8aS)-Tetrahydro-6-hydroxy-2,2-dimethyl-4,4,8,8-tetra-2-naphthalenyl-6-oxide-1,3-dioxolo[4,5-e][1,3,2]dioxaphosphepin, 98%, (99% ee) |
N/A |
100mg |
咨询 |
3-5周 |
| ZMR-08-1704 |
(3R)-(-)-2,2'-Diphenyl-[3,3'-biphenanthrene]-4,4'-diol dichloromethane adduct, min. 98% (R)-VAPOL |
[147702-16-7] |
100mg |
咨询 |
3-5周 |
| ZMR-15-6415 |
(3R,3'R)-3,3'-Di-tert-butyl-2,2',3,3'-tetrahydro-4,4'-bibenzo[d][1,3]oxaphosphole, min. 97% (99% ee) (3R,3'R)-BABIBOP |
[2214207-73-3] |
100mg |
咨询 |
3-5周 |
| ZMR-08-2014 |
(3R,5R)-(-)-3,5-Heptanediol, 99% |
[77291-90-8] |
1g |
咨询 |
3-5周 |
| ZMR-08-2037 |
(3R,6R)-(-)-3,6-Octanediol, 99% |
[129619-37-0] |
1g |
咨询 |
3-5周 |
| ZMR-08-1706 |
(3S)-(+)-2,2'-Diphenyl-[3,3'-biphenanthrene]-4,4'-diol dichloromethane adduct, min. 98% (S)-VAPOL |
[147702-15-6] |
100mg |
咨询 |
3-5周 |
| ZMR-15-6410 |
(3S,3'S)-3,3'-Di-tert-butyl-2,2',3,3'-tetrahydro-4,4'-bibenzo[d][1,3]oxaphosphole, min. 97% (99% ee) (3S,3'S)-BABIBOP |
[2207601-04-3] |
100mg |
咨询 |
3-5周 |
| ZMR-08-2015 |
(3S,5S)-(+)-3,5-Heptanediol, 99% |
[129212-21-1] |
1g |
咨询 |
3-5周 |
| ZMR-08-2038 |
(3S,6S)-(+)-3,6-Octanediol, 99% |
[136705-66-3] |
1g |
咨询 |
3-5周 |
| ZMR-16-3007 |
(4R)-4-t-Butyl-1,2,3-oxathiazolidine-2,2-dioxide-3-carboxylic acid t-butyl ester, min. 97% |
[1313705-92-8] |
1g |
咨询 |
3-5周 |
| ZMR-16-3010 |
(4R)-4-i-Propyl-1,2,3-oxathiazolidine-2,2-dioxide-3-carboxylic acid t-butyl ester, min. 97% |
N/A |
1g |
咨询 |
3-5周 |
| ZMR-15-0581 |
(4R)-4-Hydroxy-2,6-bis(3,3'',5,5''-tetrakis(trifluoromethyl)-[1,1':3',1''-terphenyl]-5'-yl)dinaphtho[2,1-d:1',2'-f][1,3,2]dioxaphosphepine-4-oxide, 98%, (99% ee) |
N/A |
25mg |
咨询 |
3-5周 |
| ZMR-15-8530 |
(4R)-4-Hydroxy-2,6-bis(3,3'',5,5''-tetrakis(tert-butyl)-[1,1':3',1''-terphenyl]-5'-yl)dinaphtho[2,1-d:1',2'-f][1,3,2]dioxaphosphepine-4-oxide, 98% |
N/A |
100mg |
咨询 |
3-5周 |
| ZMR-16-3030 |
(4R)-4-Phenyl-1,2,3-oxathiazolidine-2,2-dioxide-3-carboxylic acid t-butyl ester, min. 97% |
[1209467-60-6] |
1g |
咨询 |
3-5周 |
| ZMR-07-1082 |
(4R,4'R)-2,2'-(1,3-Dihydro-2H-inden-2-ylidene)bis[4,5-dihydro-4-tert-butyloxazole], 98%, (99% ee) |
N/A |
100mg |
咨询 |
3-5周 |
| ZMR-07-1434 |
(4R,4'R)-2,2'-(1,3-Dihydro-2H-inden-2-ylidene)bis[4,5-dihydro-4-isopropyloxazole], 98%, (99% ee) |
N/A |
100mg |
咨询 |
3-5周 |
| ZMR-07-1088 |
(4R,4'R)-2,2'-(1-Phenylpropane-2,2-diyl)bis(4,5,5-triphenyl-4,5-dihydrooxazole), 98% |
[2409652-69-1] |
100mg |
咨询 |
3-5周 |
| ZMR-07-1402 |
(4R,4'R)-2,2'-(4,6-Dibenzofurandiyl)bis[4,5-dihydro-4-phenyloxazole], 95% |
[195433-00-2] |
50mg |
咨询 |
3-5周 |
| ZMR-07-1400 |
(4R,4'R)-2,2'-(Cycloheptane-1,1-diyl)bis(4-tert-butyl-4,5-dihydrooxazole), 98%, (99% ee) |
N/A |
50mg |
咨询 |
3-5周 |
| ZMR-07-1396 |
(4R,4'R)-2,2'-(Cycloheptane-1,1-diyl)bis(4-phenyl-4,5-dihydrooxazole), 98%, (99% ee) |
N/A |
50mg |
咨询 |
3-5周 |
